Good to spread all over the world #IBCG, and to share knowledge and daily practice! #bladdercancer. Fundació Puigvert Barcelona

#potomac trial published in #Lancet : Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial doi.org/10.1016/S0140-… Another step forward in #NMIBC. Fundació Puigvert Barcelona

Is it presented the TYPE OF #TURB. Pre #cystectomy? Complete, staging, biopsy…? Even no doubt about the results, important to know the methodology and distribution. #ESMO25

1/4 IMVIGOR011 shows ctDNA is a useful predictive and prognostic tool post cystectomy in muscle invasive bladder cancer #ESMO25 . ctDNA positive patients had DFS and OS benifits with atezolizumab. ctDNA negative patients are at a low risk of relapse/cancer death. OncoAlert

#APU2025 in Porto: excelent urological meeting! Sharing with good friends! ⁦Arnulf Stenzl⁩, Dr Miguel Ramos, Dr Arnaldo Figueiredo, Dr Avelino Fraga. ⁦European Association of Urology (EAU)⁩. ⁦Fundació Puigvert Barcelona⁩.

Surgical Immersions in #NMIBC with the suport of #olympus. ⁦Fundació Puigvert Barcelona⁩ and #Surgical training and better vision in #bladdercancer. #Europe and #Africa together!

🚨 Join us to get some news about the contemporary management of #UTUC Key Opinion Leadership from all the 🌏 Seth Lerner Jeremy Teoh Shilpa Gupta ⏱️ the 15.15 📍Room Tinto 0 Jeremy Teoh Société Internationale d'Urologie Journal

Damos la bienvenida a ⁦Fundació Puigvert Barcelona⁩ a nuevos colegas: Dr Gonzalo Fuentes Flores de Chile (Rec), @HerediaAnet_uro (Onco) de Mejico Dr Furkan Ozsoy de Turquia (Furkan Özsoy) (Onco) y Alejandro Tamayo (Pedia) de Mejico. Les deseamos una buena estancia entre nosotros!!

🧬 Urine tumor DNA to stratify recurrence risk after atezolizumab in BCG-unresponsive NMIBC In a secondary analysis of the SWOG S1605 trial, urine tumor DNA (utDNA) profiling with the UroAmp assay was used to stratify the risk of response to treatment with atezolizumab in

⚡️On NEJM : IMvigor011 shows ctDNA-guided adjuvant therapy works in MIBC. In ctDNA+ post-cystectomy pts, atezolizumab improved DFS (HR 0.64; 9.9 vs 4.8 mo) and OS (HR 0.59; 32.8 vs 21.1 mo). ctDNA-negative pts avoided tx with 95% DFS at 1 yr. #BladderCancer Tom Powles

Bienvenido!! Welcome to the club!

Ara, a Ràdio Barcelona (96.9 FM) en directe, el director del Servei d’Urologia debla Fundació #Puigvert, el Dr. Joan Palou Redorta ens parla sobre el càncer de pròstata i la salut masculina, al costat del pacient Jordi Guillamet, amb Anna Puigboltas! 🩵 #Novembreblau

Ashish M. Kamat, MD, MBBS Emanuele Crupi Andrea Necchi IBCG Eur Urol Focus Max Kates Petros Grivas Shilpa Gupta Sia Daneshmand, M.D. Philippe spiess Omar Alhalabi, MD Joan Palou Redorta Neeraj Agarwal, MD, FASCO Laura Bukavina Kent Mouw Ready for primetime? cT0 is not pT0 MRI needs validation ctDNA negative in niagara not strongly related to pCR

Still similar doubts…but trying to reach better approach to preserve “bladders”! Let’s continue…

A pleasure to have you with us! Safe trip back!

Great presence of the Stone Team from Fundació Puigvert Barcelona at the #ICE25! We are presenting 2 videos and 3 posters, showing our experience in stone management. Proud of our team! European Association of Urology (EAU) Oriol Angerri Andres Kanashiro Lucio Fila Paolo Verri Paula Izquierdo Pedro Hernández Peñalver

Congratulations Jeremy! Going to the future…

⚡️ Refining endpoints for bladder-sparing strategies in MIBC: An international consensus outlines a unified definition of clinical complete response and reinforces event-free survival as the most reliable primary endpoint for upcoming perioperative trials. #BladderCancer

A pleasure to be at #ICE25. What a brainstorming congress among the best endourologists from all over the world. I imagined this when I decided to be a researcher/surgeon. Fundació Puigvert Barcelona Alberto Breda Alejandra Bravo-Balado, MD, FEBU Andrea Gallioli Andres Kanashiro AnnaBujonsTur Lucio Fila Oriol Angerri Pedro Hernández Peñalver

Excelent job Olivier and team! As usual!!